Posted by Michael Wonder on 27 Apr 2021
Reata announces FDA accepted for filing the NDA for bardoxolone for the treatment of patients with chronic kidney disease caused by Alport syndrome
26 April 2021 - Application assigned a PDUFA date of 25 February 2022.
Reata Pharmaceuticals today announced that the U.S. FDA accepted for filing the new drug application for bardoxolone methyl for the treatment of patients with chronic kidney disease caused by Alport syndrome.
